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Summary
We have recently shown that CD30, a member ofthe tumor necrosis factor/nerve growth fac-
tor receptor superfamily, is preferentially expressed by human T cell clones producing T helper
(Th) type 2 cytokines. We report here that costimulation with an agonistic anti-CD30 mono-
clonal antibody enhanced antigen (Ag)-induced proliferation and cytokine secretion by estab-
lished human Th2 and Th0 clones. Moreover, costimulation of peripheral blood mononuclear
cells with the same anti-CD30 monoclonal antibody resulted in the preferential development
ofAg-specific T cell lines and clones showing a Th2-like profile of cytokine secretion. In con-
trast, early blockade in bulk culture ofCD301igand-CD30 interaction shifted the development
of Ag-specific T cells towards the opposite (Th1-like) phenotype. Taken together, these data
suggest that CD30 triggering ofactivated Th cells by CD30 ligand-expressing Ag-presenting cells
may represent an important costimulatory signaling for the development of Th2-type responses.
D4+ T cells can be separated both functionally and
based on the cytokines they produce in response to
Ag (1). Thl cells secrete IL-2, TNF-R, and IFN-y, and,
because of the macrophage-activating property of IFN-'Y,
they are the principal effectors of cell-mediated immunity
against intracellular microbes as well as of delayed-type hy-
persensitivity reactions (2, 3) . However, Th2 cells produce
IL-4, IL-5, and IL-10, which promote production of anti-
bodies (including IgE), differentiation, and activation of
eosinophils, and inhibit several macrophage functions. Th2
cells mainly develop in response to helminths as well as to
common environmental allergens (4, 5).
Several studies in both murine and human models have
clearly shown that the development ofboth naive and mem-
ory CD4+ T cells into the Th1 or Th2 functional phenotype
is mainly regulated by cytokines (6, 7). IL-4 induces Th to
differentiate into IL-4-producing cells and diminishes their
priming for IFN--y production, thus polarizing the response
toward the Th2 state (7, 8); IL-12 strikingly enhances
priming for IFN-y production, and, through the produc-
tion of IFN-y by T cells and NK cells, IL-12 diminishes
priming for IL-4 production, thus polarizing the response
toward a Th1 state (9, 10). However, these findings do not
fully and directly explain which features of a natural or in-
tentional immunization elicit the distinctive production of
the inducing cytokines or other possible factors that may
determine the phenotype ofcytokine-producing Th cells.
Recently, we have shown that CD30, a member ofTNF
receptor superfamily (11), is preferentially expressed by Th2-
type CD4+ T cell clones (12) as well as by CD8+ T cell
clones showing a Th2-like profile ofcytokine secretion (13).
The natural ligand for CD30 (CD30L)' has been cloned
(14), and it has been found to be expressed by B lympho-
cytes (15) as well as by a subset of activated macrophages
and T cells (16). We have therefore addressed the question
of whether costimulation of CD30 had any functional role
in the Ag-induced response of established Th2 clones as
well as in the in vitro development and/or maturation of
Th2 cells.
Results showed that CD30 costimulation potentiated
both Ag-induced proliferative response and cytokine pro-
duction by established Th2 and Th0 clones. More impor-
tantly, CD30 costimulation favored the in vitro develop-
ment of Ag-specific T cells toward the Th2-like profile,
whereas blockade of CD30L-CD30 interaction had an in-
hibitory effect on the development of Ag-specific memory
T cells into the Th2-like phenotype. Thus, CD30 trigger-
ing on Ag-reactive T cells by APC expressing CD30L may
provide a critical costimulatory signal for the development
ofTh2 responses.
'Abbreviations used in this paper: CD30-Fc, soluble form ofCD30 fused to
the Fc region of human IgG1; CD30L, natural ligand for CD30; Lol p I,
Lolium perenne group 1; TES, excretory-secretory Ag of Toxocara canis;
TT, tetanus toxoid.
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Reagents.
￿
Excretory-secretory Ag of Toxocara cams (TES) was
purchased by Biokema (Lausanne, Switzerland), tetanus toxoid
(TT) was kindly provided by Istituto Sieroterapico e Vaccinogeno
Sclavo (Siena, Italy), andpurified Lolium perenne group I (Lol p I)
allergen was a gift from Dr. A. A. Ansari (Johns Hopkins Univer-
sity, Baltimore, MD). Recombinant human IL-2 was a kind gift
from Eurocetus (Milano, Italy), and recombinant human IL-5
was purchased from Amgen Biologicals (Thousand Oaks, CA).
PHAwas purchasedfrom Gibco Laboratories (Grand Island, NY).
Anti-CD3, anti-CD4, and anti-CD8 mAb were purchased from
Ortho Pharmaceuticals (Raritan, NJ). Anti-CD30 mAb (Ber-H2)
was purchased from Dako (Glostrup, Denmark). Anti-CD30 ag-
onistM44mAb, anti-CD30L M81 mAb, and the soluble form of
CD30 fused to the Fc region of human IgG1 (CD30-Fc) were
prepared by Immunex (Seattle, WA). Polyclonal rabbit anti-human
IL-4 waspurchased from Genzyme Corp. (Cambridge, MA).
Generation ofT Cell Lines and Clones.
￿
PBMC were obtained ei-
ther from healthy volunteers who had been vaccinated with TT
and showed a lymphoproliferative response in vitro to TES or
from atopic grass-sensitive subjects showing immediate skin reac-
tivity to Lol p I allergen. Ag-specific T cell lines were generated
as previously described (17). Briefly, PBMC prepared by density
gradient centrifugation were resuspended (106 in 2 ml) in RPMI
1640 medium supplemented with 2 MM L-glutamine, 2 X 10-5
M 2-ME, and 5% heat-inactivated human serum (complete me-
dium) andstimulated with TES, Lolp 1 (2 Ft,g/ml), or TT (0.5 ltg/
ml) in 24-well plates for 6 d in the presence of immobilized anti-
CD30 agonist M44 mAb (10 Rg/ml) or isotype control (murine
IgG1), soluble anti-CD30L M81 mAb (5 Rg/ml) or its isotype
control (murine IgG2b), and soluble CD30-Fc (1 N,g/ml) or its
control (human IgGl). After 6 d IL-2 was added (20 U/ml), and
cultures were continued for an additional 5 d. Ag specificity was
assessed by measuring [3H]TdR uptake after 60 h of stimulation
with the appropriate Ag in the presence of irradiated autologous
non-T cells as APC, as reported (17) . To generate T cell clones,
T cell blasts obtained from the different T cell lines were seeded
under limiting dilution conditions (0.3 cells per well) in round-
bottomed microwell plates containing 105 irradiated PBMC (as
feeder cells), PHA (0.5% vol/vol), and IL-2 (20 U/ml), as re-
ported elsewhere in detail (17). Cell surface marker analysis of T
cell clones was performed on a cytofluorimeter (Cytoron Abso-
lute; Ortho Pharmaceuticals), and Ag specificity was assessed by
measuring [3H]TdR uptake after 60 h of stimulation with the ap-
propriate Ag, as reported (17).
Characterization of the Cytokine Profile of T Cell Lines and Clones.
To induce cytokine production by T cell lines or clones in re-
sponse to their specific Ag, 106 T cell blasts were cocultured in 1
ml complete medium with 5 X 105 irradiated autologous APC
andthe specific Ag (0.5-2 Rg/ml) (17). After 48 h, culture super-
natants were collected, filtered, and stored in aliquots at -70°C
until used. To induce cytokine production in response to PHA,
T cell blasts were resuspended at 106/ml complete medium and
cultured in the presence ofPHA (l %vol/vol). After36 h, culture
supernatants were collected, filtered, andstored in aliquots at -70°C
until used. Supernatants were assayed for IFN-y, TNF-[3, IL-4,
and IL-5 content. The quantitative determinations of IFN-y or
TNF-[3 and IL-4 were performed by commercial assays (Bio-
Source International, Camarillo, CA; or Quantikine, R&D Sys-
tems, Minneapolis, MN, respectively). For the measurement of
IL-5, the murine LyH7.B13 cell line was used as source of indica-
tor cells, as detailed elsewhere (17). Supernatants showing IFN-y,
TNF-[3, IL-4, or IL-5 levels 5 SD over themean levels in control
supernatants derived from irradiated feeder cells alone were re-
garded as positive. T cell clones able to produceIFN-yandTNF-(3,
but not IL-4 or IL-5, were categorized as Thl; clones able to pro-
duce IL-4 and/or IL-5, but not IFN-y and/or TNF-R, were cat-
egorized as Th2; andclones producingboth IFN-y (and/orTNF-(3)
and IL-4 or IL-5 were categorized as ThO.
Results
CD30 Costimulation Enhances Ag-induced Proliferation and
Cytokine Production by Established CD4+CD30+ T Cell Clones.
We first investigated the responsiveness ofa panel ofCD30+
and CD30- CD4+ T cell clones either to stimulation with
an anti-CD30 agonist (M44) mAb or to costimulation with
M44 mAb and the specific Ag. To this end, six Thl, six
ThO, and six Th2 clones (whose mean CD30 expression was
<10, 14-56, and 41-87%, respectively) were cultured for3 d
in the presence of immobilizedM44 alone or M44 plus Ag-
primed autologous APC, and their proliferative response was
assessed. No response to M44 mAb was seen in the absence
ofAg-primedAPC stimulation (data not shown); however,
Ag-driven proliferation was significantly increased by M44
mAb (P <0.01) in both ThO and Th2 (CD30+) but not in
Thl (CD30-) T cell clones (Table 1). To ascertain whether
the costimulatory activity of immobilized anti-CD30 might
be ascribed to CD30 cross-linking, Ag-induced proliferation
of two Thl, two ThO, and two Th2 clones was assessed in
microplates coated with graded concentrations of M44
mAb or in thepresence ofsoluble M44 followed by a poly-
clonal rabbit anti-mouse Ig Ab. As shown in Table 2, the
Table 1 .
￿
Costimulatory Effect ofImmobilized Anti- CD30
Agonist M44 mAb on Antigen-induced Proliferation of ThO and Th2
T Cell Clones
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T cell clones specific for TT, Lol p I, or TES were stimulated for 36 h
with PHA, and cell-free supernatants were assayed fortheir IL-4, IL-5,
and IFN-y content as reported (17). Six Thl, six ThO, and six Th2
CD4+ clones, whose T cell blasts showed membrane CD30 expression
of<10, from 14 to 56, andfrom 41 to 87%, respectively, were costim-
ulated with insoluble M44 (10 wg/ml) or its isotype control in thepres-
ence of autologous APC and the specific Ag (TT, 0.5 ltg/ml; TES or
Lol p I, 2 jig/ml) as described. After 3 d, [3H]thymidine uptake was
evaluated. Results express mean values (:' SD) of triplicate cultures for
each series ofsix clones.
T cell clones Costimulant
Mean (± SD)
[3H]thymidine
uptake
Mean (± SD)
% increase
cpm X 10-3
Th1 Isotype control 9.5 ± 2.3
M.44 10.6±2.7 10.4± 11
ThO Isotype control 11 .2 ± 4.5
M.44 14.5±5 .1 29.5±13
Th2 Isotype control 9.3 - } 3.8
M.44 16.1 ± 6.6 73.1 ± 28Table 2.
￿
Costimulatory Activity ofAnti-CD30Agonistic M.44 mAb Is Due to CD30 Cross-linking
costimulatory effect of immobilized M44 mAb on Ag-
induced proliferation of both ThO and Th2 clones was dose
dependent and was substantially inhibited by the addition
of CD30-Fc. In the same experiment, costimulation ofAg-
induced proliferation was also induced by soluble M44 fol-
lowed by a polyclonal rabbit anti-mouse Ig Ab, suggesting
that the activity of the agonist anti-CD30 mAb could be
ascribed to CD30 cross-linking. We then asked whether co-
stimulation of T cell clones with insoluble M44 mAb could
also influence their ability to produce cytokines. To answer
this question, IFN-y, IL-4, and IL-5 production was mea-
sured in culture supernatants of the same Thl, ThO, and
Th2 clones cultured for 48 h in the presence of M44 mAb
(or its isotype control), with or without the addition ofAg-
primed APC. Stimulation with M44 mAb alone did not re-
sult in the production of any detectable cytokine, whereas
costimulation with M44 mAb, but not with isotype con-
trol, significantly increased both IL-4 and IL-5 Ag-induced
production in all Th2 clones (P <0.001) and, to an even
lower extent, in all ThO clones (P <0.05)_ Under the same
conditions, M44 mAb also significantly enhanced Ag-induced
IFN-y production by ThO clones (P <0.05), but it had vir-
tually no effect on IFN-y production by Thl clones (Fig.
1) . No qualitative changes in the original cytokine profile of
established T cell clones were observed, inasmuch as Thl
clones were not induced to secrete IL-4 or IL-5, nor were
Th2 clones induced to secrete IFN-y.
CD30 Triggering Favors the Preferential Expansion In Vitro
of T Cells Producing Th2-Type Cytokines. Thepossibility that
agonistic signals delivered through CD30 might induce the
preferential expansion o£ Th cells producing Th2-type cy-
tokines was then investigated. To this end, TT-specific T
cell clones were generated from three different donors by
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Four TES-specific clones (two Th0 and two Th2), whose T cell blasts showed membrane CD30 expression of 19, 32, 56, and 67%, respectively,
were stimulated with TES in the presence of graded concentrations of insoluble M.44 or its isotype control with or without addition of soluble
CD30-Fc. Clones were also costimulated with soluble M.44 or control Ig, followed by a polyclonal rabbit anti-mouse Ig antibody. After 3 d,
[3H]thymidine uptake was evaluated. Results express mean values of triplicate cultures. Values in parentheses indicate the mean percent increase of
proliferation in comparison with the appropriate controls.
stimulating their PBMC with specific Ag in the absence or
presence of insolubilized M44 mAb or of its isotype con-
trol. As shown in Fig. 2 A, in the series of 108 CD4+ T cell
clones derived from M44 mAb-costimulated lines, the pro-
portion of clones able to produce Th2-type cytokines (IL-4
and IL-5) was significantly increased, whereas the propor-
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Figure 1.
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Costimulatoryeffect of immobilized anti-CD30 agonist M44
mAb on Ag-induced cytokine production by six Th1, six ThO, and six
Th2 established T cell clones. To induce cytokine production, 106 T cell
blasts from each clone were seeded in tubes coated with M44 mAb (10
Wg/ml) or its isotype control (murine IgGl) and cultured in 1 ml in the
presence of 5 X 105 irradiated autologous APC andthe specific Ag (TT,
0.5 pg/ml; Lol p I or TES, 2 Ltg/ml). After 48 h, culture supernatants
were collected, filtered, and assessed for cytokine content. Results repre-
sent the mean (± SD) percent increase of cytokine production over val-
ues measured in supernatants from the same T cell clones cultured in
tubes coated with isotype control. Values of cytokine production were
68-232 U/ml IFN-h <30 pg/ml IL-4, and <0.2 U/ml [L-5 in control
cultures of Thl clones; 52-208 U/rnlIFN-y, 120-3,600 pg/ml IL-4, and
0.9-23.0 U/ml IL-5 in control cultures ofTh0 clones; <3 U/ml IFN-y,
90-4,800 pg/mlIL-4, and 3.2-36.5 U/ml IL-5 in controlcultures ofTh2
clones.
Culture condition T.61 (ThO)
Antigen-induced [3H]thymidine
T22 (Th0)
uptake (cpm X 10-3)
T.36 (Th2) T.42 (Th2)
Insoluble control Ig (50 Htg/ml) 8.61 12.11 8.90 12.98
Insoluble M.44 (10 N,g/ml) 11 .15 (37) 16.32 (30) 15.81 (75) 23.72 (81)
Insoluble M.44 (2 N,g/ml) 10.65 (25) 15 .03 (22) 14.21 (61) 20.66 (62)
Insoluble M.44 (0.4 N,g/ml) 9.17(8) 13.85 (8) 10.92 (20) 16.19 (26)
Insoluble M.44 (10 ~Lg/ml)
+ CD30-Fc (5 wg/ml) 8.32(3) 13.12(5) 11 .75 (30) 17.12 (31)
Soluble control Ig (5 ltg/ml)
+ anti-mouse Ig (50 Rg/ml) 8.36 12.02 9.07 12.47
Soluble M.44 (5 jig/ml)
+ anti-mouse Ig (50 Wg/ml) 12.09 (45) 15.89 (32) 16.13 (78) 21 .70 (74)A
B
IFN-Y TNF-0 IL-4 IL-5
Thl ThO Th2
O Ag+control IgG1
" Ag+ M.44 mAb
Figure 2.
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Costimulation with anti-CD30 agonist M44 mAb favors the
preferential expansion ofT cells producing Th2-type cytokines. Two se-
ries of TT-specific T cell lines were raised in the presence of insoluble
M44 or its isotype control, as described in Table 1. On day 11, T cell blasts
were cloned (03 cells per well) in the presence of PHA (1% vol/vol) and
IL-2 (20 U/ml) . A total number of 108 TT-specific CD4+ clones derived
from M44-costimulated T cell lines were compared with 90 TT-specific
CD4+ clones derived from isotype control-costimulated lines for their
ability to produce IFN-y, TNF-I3, IL-4, and IL-5 upon 36 h ofstimula-
tion with PHA (A). The two series of TT-specific clones were also com-
pared for their distribution ofTh profiles (B). Results represent mean per-
cent values ± SE. Statistical analysis was performed with the X2 test.
tion of clones producing Thl-type cytokines (IFN-y and/
or TNF-(3) was significantly reduced in comparison with
those found in the 90 clones derived from TT-specific lines
costimulated with isotype control. When the two series of
TT-specific clones were compared for the distribution of cy-
tokine profiles, a significant reduction of Thl (14 vs 43%)
and an increase ofboth Th0 (67 vs 50%) and Th2 (19 vs 7%)
phenotypes were found in the series costimulated with M44
mAb (Fig. 2 B). These data suggest that costimulation via
CD30 favored the preferential development and/or the se-
lective growth of Th cells able to produce Th2-type cyto-
kines.
Blockade of CD30-CD30L Interaction Results in the Out-
growth of Ag-specific T Cell Lines and Clones Able to Produce
Thl-Type Cytokines and Inhibits the Development of Th2-like
T Cells. In view ofthe effects ofanti-CD30 agonist mAb,
we asked whether blockade of the interaction between
CD30 and its natural ligand (CD30L) could also influence
the cytokine secretion profile ofAg-specific T cells. To this
end, Lol p I-specific T cell clones were generated from
three different donors by stimulating their PBMC with Lol
p I alone or Lol p I plus anti-CD30L mAb (M81), CD30-
Fc fusion protein, or anti-IL-4 Ab. As expected, among
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the 84 CD4+ T cell clones generated in presence of anti-
IL-4 Ab, the proportion of those showing a Thl-like pro-
file was remarkably increased with concomitant reduction
of Th2-like clones in comparison with the 86 CD4+ T cell
clones derived from Lol p I stimulated in presence of non-
immune rabbit Ig (Fig. 3). Likewise, either in the series of
101 CD4+ T cell clones derived from anti-CD30L mAb-
conditioned cells or in the series of 99 clones derived from
CD30-Fc-treated cells, the proportions of clones able to
produce IL-4 and IL-5 were significantly reduced, whereas
the proportion of clones producing IFN-y was significantly
increased in comparison with that found in the 86 Lol p I-spe-
cific control clones. When the different series ofclones were
compared for their distribution of cytokine profiles, a sig-
nificant increase of Thl (34 and 31 vs 15%) and a decrease
of Th2 (29 and 37 vs 58%) phenotypes were found in the
series derived from cells conditioned with either anti-
CD30L mAb or CD30-Fc (Fig. 3) .
We finally asked whether blockade of CD30L-CD30
interaction was effective only in the early phases of T cell
activation by Ag, or whether it could still influence the cy-
tokine secretion profile of Ag-specific T cells if applied
later. To this end, the effects ofanti-CD30L M81 mAb and
CD30-Fc were assessed in kinetics experiments in which
the two reagents were added at different time intervals (day
0, 3, and 6) to PBMC cultures of seven donors stimulated
with TES, TT, or Lol p I Ags. As expected, early blockade
ofCD30L-CD30 interaction by either M81 mAb or CD30-
Fc fusion protein induced the outgrowth of Ag-specific T
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Figure 3.
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Blocking of CD30-CD30L interaction hampers the devel-
opment of Ag-specific T cell clones into Th2-like cells. PBMC from
three grass pollen-sensitive donors were stimulated with Lol p I Ag in the
presence of anti-CD30L M81 mAb (5 N.g/ml), pooled routine and rabbit
control Ig (10 p,g/ml), CD30-Fc (1 pg/ml), or rabbit polyclonal anti-IL-4
Ab (10 p.g/ml). T cell blasts from each T cell line were cloned as detailed in
Table 1 . A total of101 Lol p I-specific CD4+ clones generated in the pres-
ence ofM81 mAb, 86 Lol p I-specific CD4+ clones generated in the pres-
ence ofcontrol Ig, 99 Lol p I-specific CD4+ clones generated in the presence
of CD30-Fc, and 84 Lol p 1-specific CD4+ clones generated in the pres-
ence ofanti-IL-4 Ab were compared for their ThI, ThO, or Th2 profiles.
Results represent mean percent values ± SE. Statistical analysis was per-
formed with the X2 test.2004
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Figure 4.
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Kinetics of the effects ofblocking of CD30-CD30L interac-
tion by anti-CD30L mAb or CD30-Fc fusion protein. PBMC (106/ml)
from five donors were stimulated with TES, TT, or Lol p I Ags in the
presence ofand-CD30L M81 mAb (5 Wg/ml), its isotype control, or CD30-
Fc (I LLg/ml), added at different time intervals (day 0, 3, and 6). On day 6,
IL-2 (20 U/ml) was added, and the cultures were continued for an addi-
tional 5 d. At the end of culture period, T cell lines were recovered and
resuspended (1O'/ml) in fresh medium supplemented with PHA. After
36 h, supernatants were assayed for IL-4, IL-5, and IFN-y content. Re-
sults represent mean ± SD percent increase/decrease ofcytokine produc-
tion versus values measured in supernatants from the corresponding T cell
lines cultured in the presence ofisotype control.
cell lines producing lower amounts of IL-4 and IL-5, but
higher amounts (approximately a twofold increase) of IFN-y
than did their corresponding control T cell lines (Fig. 4). In
contrast, when addition of the two CD30L-binding re-
agents was delayed to day 6 after Ag stimulation, T cell lines
showed an IL-4 and IL-5 production almost comparable to
that exhibited by their control lines. The same effect was
seen for IFN-y production in Ag-specific T cell lines in-
duced with late addition of CD30-Fc. However, blocking
of CD30L by anti-CD30L mAb, even if delayed until day
6, was still effective in inducing Ag-specific T cell lines able
to secrete higher amounts of IFN-y than did the correspond-
ing control lines (Fig. 4).
The results of this study indicate that CD30 plays an im-
portant role in both functional activity and development
of Th2-like human CD4+ T cells. CD30, originally de-
scribed as a marker of Hodgkin's and Reed-Sternberg cells
of Hodgkin's lymphoma (18) and as an activation molecule
of lymphoid cells that are detectable in scanty number
around the lymphoid follicles in lymphoid tissues (19), has
been recently identified as a cytokine receptor belonging to
the TNF receptor superfamily (11). CD30 exists as mem-
brane glycoprotein chains of 105 and 120 kD, derived from
a 90-kD precursor and a 57-kD intracellular form (20) .
The extracellular form of CD30 is proteolytically cleaved
to produce an 88-kD soluble form of the molecule, which
is released by CD30-expressing cells in vitro and in vivo
(21) . In short-term cultures, CD30 expression is inducible
on T and B cells transformed by virus (e.g., by human T
cell lymphotropic virus types 1 and 2 or Epstein-Barr virus)
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(22) and on a small proportion of anti-CD3-stimulated
CD45RO+ (memory) T cells, which exhibit enhanced B
cell helper activity and produce both IFN-y and IL-5, thus
resembling ThO cells (23, 24). We have recently shown
that, at the clonal level, membrane CD30 is preferentially
expressed by human T cells producing Th2-type cytokines,
e .g., Th2- and ThO-like cells (12, 25) . The discrepancy be-
tween our findings and those reported by Alzona et al. (24,
26) is only apparent and probably relates to the differences
in the experimental approach used. It is likely that the cells
expressing CD30 in response to the short-term and APC-
independent polyclonal stimulation used by Alzona et al.
represent precursors of T cells that predominantly develop
into ThO cells. In their system, indeed, CD30+ T cells seem
to be ThO-like cells able to provide optimal B helper cell
activity (24), but still lacking IL-4 production. In contrast, a
clearer separation ofThl, ThO, and Th2 cells can be achieved
in our model of Ag-specific T cell lines and clones, where
repeated T cell stimulation in the presence of autologous
APC makes IL-4 secretion easily detectable. The demon-
stration that CD30 triggering by anti-CD30 agonist Ab en-
hances Ag-induced proliferation and cytokine production
by Th2 and ThO but not by Thl clones strongly supports
our previous findings (12, 25) . Thus, it appears that CD30
is not only preferentially expressed on Th cells producing
Th2-type cytokines, but it also acts as a costimulatory mol-
ecule whose cross-linking is able to promote both expan-
sion and effector function of Th2-like cells.
The most interesting observation emerging from this study,
however, is that, at least in vitro, CD30 costimulation also
appears to play an important role in the development of
Th2-like cells. First, the addition in bulk culture before
cloning of agonist anti-CD30 Ab resulted in the develop-
ment of higher proportions of Th2-like T cell clones than
those obtained in parallel cultures stimulated with Ag and
isotype control. More importantly, the blockade of CD30L-
CD30 interaction by addition in bulk culture of anti-CD30L
Ab or a soluble CD30-Fc fusion protein favored the devel-
opment ofhigher numbers ofAg-specific Th cells showing
the opposite (Thl-like) phenotype. Whereas the enrichment
of Th2 cells induced by costimulation with anti-CD30 Ab
may simply be due to a selection process that neglects Thl
cells, the shift to the Thl profile resulting from blockade of
CD30L-CD30 interaction more likely reflects a true change
in the differentiation process ofAg-stimulated Th cells grow-
ing in culture. Only early blockade of CD30L-CD30 inter-
action was indeed effective in inhibiting the development
ofa prevalent Th2 phenotype, whereas the lateraddition of
either anti-CD30L Ab or soluble CD30-Fc had poor or no
shifting effect. Thus, it is reasonable to suggest that the in-
teraction of Ag-activated memory T cells expressing CD30
with CD30L+ APCs represents an effective costimulatory
signal for their differentiation into T cell clones producing
Th2-type cytokines. Whether different APC can differ-
ently express CD30L is still unclear. CD30L is expressed by
a subset ofLPS-activated macrophages (16) and by the ma-
jority of B lymphocytes (15) ; no data regarding CD30 ex-
pression on dendritic cells are available.The importance of costimulatory signals provided by
APCs for optimal activation of T lymphocytes is well known.
Several receptor-counterreceptor pairs mediate adhesion be-
tween APCs and T cells and deliver activating signals to T
cells. The interaction of137 expressed on macrophages and
dendritic cells with its CD28 receptor on T cells represents
the best characterized example of this costimulation (27,
28) . The B7-CD28 interaction has recently been found to
promote optimal proliferation of terminally differentiated
ThI clones in both mice and humans (29-33) . More impor-
tantly, in Leishmania major-infected mice, in vivo blockade
ofthe B7-CD28 interaction at the time ofparasite inocula-
tion had a profound suppressive effect on the maturation of
Th2 but not Thl cells, suggesting that important functional
differences may underlie the costimulatory signals used by
these two subsets of CD4+ T cells (34). Accordingly, the
blockade of CD30L-CD30 interaction might also interfere
with a critical pathway required for in vitro Th2 develop-
ment. This finding raises the question of whether such an
interaction can inhibit the production of IL-12, which is
considered the most important signal for the maturation of
Thl cells (9, 10), or whether, alternatively, it may favor the
early production of IL-4, which is required for the differ-
entiation of both naive (7) and memory (8) CD4+ T cells
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